Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

Pedersen COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide ...

The weight-loss drug eloralintide shows up to 20% body weight reduction in trial, offering hope for obesity treatment beyond ...

MONDAY, Nov. 24, 2025 (HealthDay News) — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in ...

Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock ...

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding ...

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

Eli Lilly has hit $1 trillion in market value, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...

Next generation weight loss drugs are prohibitively expensive for many in the US who would benefit from taking them—and may remain so, thanks to the phenomenon of patent thickets. Paige Huffman ...